Alector Announces Pricing of Public Offering of Common Stock
17 janv. 2024 08h54 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced the pricing of an...
Alector Announces Proposed Public Offering of Common Stock
16 janv. 2024 16h01 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it intends to...
Alector to Host Two Virtual Research and Development Events Highlighting TREM2 and Progranulin Programs
28 nov. 2023 07h00 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will host two...
Alector to Participate in the Stifel Healthcare Conference
08 nov. 2023 07h00 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will...
Alector Reports Third Quarter 2023 Financial Results and Provides Business Update
07 nov. 2023 16h05 HE
|
Alector, Inc.
Achieved Q4 2023 target enrollment in pivotal INFRONT-3 Phase 3 latozinemab clinical trial with 103 symptomatic FTD-GRN participants Enrollment completed in the INVOKE-2 Phase 2 clinical...
Alector Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
27 oct. 2023 07h00 HE
|
Alector, Inc.
--101 symptomatic FTD-GRN participants enrolled in INFRONT-3 -- SOUTH SAN FRANCISCO, Calif., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company...
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
07 sept. 2023 07h00 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that it has...
Alector to Participate in Upcoming Healthcare Conferences
31 août 2023 07h00 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will...
Alector Reports Second Quarter 2023 Financial Results and Provides Business Update
03 août 2023 16h05 HE
|
Alector, Inc.
Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 ...
Alector to Host Mid-Year Earnings Conference Call
27 juil. 2023 08h30 HE
|
Alector, Inc.
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced it will host a...